Aligos posts Phase 1 results for ALG-097558 in hepatic impairment study
Trial results for the COVID-19 antiviral candidate ALG-097558 were posted, comparing pharmacokinetics in subjects with moderate hepatic impairment versus normal liver function.
Aligos Therapeutics had one notable regulatory update in its trial record this week.
- ALG-097558, an oral antiviral candidate for COVID-19, completed a Phase 1 study evaluating pharmacokinetics, safety, and tolerability in subjects with moderate hepatic impairment and healthy subjects with normal hepatic function. The study was non-randomized with a parallel design and enrolled 16 participants1, with primary completion on 2025-07-16 and results first posted 2026-08-05. The study's primary purpose was to characterize the effect of hepatic impairment on the plasma pharmacokinetics of ALG-097558 following multiple twice daily oral doses.1 The National Institute of Allergy and Infectious Diseases (NIAID) is listed as a collaborator on the study, which is sponsored by Aligos Therapeutics.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.